Biogen (BIIB) Tops Q2 EPS by $1.62, Raises FY Guidance

Biogen (NASDAQ: BIIB) reported Q2 EPS of $9.15, $1.62 better than the analyst estimate of $7.53. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.48 billion.

GUIDANCE:

Biogen sees FY2019 EPS of $31.50-$32.30, versus the consensus of $29.70. Biogen sees FY2019 revenue of $14-14.2 billion, versus the consensus of $13.95 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Evercore cuts HPE rating amid 'tougher setup'
• BofA sees just 2% upside for the S&P 500 over the next 12 months
• Akebia doses first patient in Phase 2 kidney disease trial